The study consists of an open-label AXS-14 treatment period followed by a randomised, double-blind treatment period.

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous ...

Axsome Therapeutics AXSM announced the initiation of the phase III study called FORWARD with the dosing of the first patient, ...

Chronic pain affects more than 50 million Americans, yet for decades, treatment options for pain that persists in the absence ...

A study conducted by British researchers found that patients with fibromyalgia (FM) reported improved quality of life following use of medical cannabis pro | Health And Medicine ...

Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced ...

Interdisciplinary multimodal pain treatment is associated with modest improvements in quality of life among adults with ...

Effective Sjögren’s management demands a strict separation between symptomatic relief for sicca and immunosuppression for ...

As of Friday, January 23, Tonix Pharmaceuticals Holding Corp.’s TNXP share price has dipped by 5.26%, which has investors ...

Once used mainly for distraction, VR is now being studied as a way to retrain the brain’s pain pathways—especially for people ...

What investors want to see is Tonix Pharmaceuticals ( TNXP) move away from a cash-burning R&D company and into having more of a recurring revenue base from its current approved drugs. As of now, the ...

A new protocol will phenotype chronic ocular surface pain to identify nociplastic CNS drivers using ocular exams, sensory ...